

HPAP-073 Donor Summary



HPAP	073	UNOS		
Recovery OPO	NJTO - NJ ORGAN and Tissue Sharing Network	Allocation Via	UPENN <input type="checkbox"/> nPOD <input checked="" type="checkbox"/>	
Age (years)	24	DCD	YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>	
Race	Hispanic/Latino: Mexican	DBD	YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>	
Sex	M <input checked="" type="checkbox"/> F <input type="checkbox"/>	Admission to Cross Clamp	107 Hours 40 Mins.	
ABO (Rh)	O	Cross Clamp Time	11/11/2020 03:40 EST	
BMI (Kg/m²)	25.926	Cold Ischemia Time*	Hours Mins. No Islet Isolation	
Weight (kg)	84			
Height (cm)	180			
Cause of Death	CEREBROVASCULAR/STROKE	Preservation Solution	UW <input checked="" type="checkbox"/> HTK <input type="checkbox"/>	
Mechanism of Injury	INTRACRAINIAL HEMORRHAGE/STROKE	Organs Recovered	Heart <input checked="" type="checkbox"/> Lung <input checked="" type="checkbox"/> right lung <input type="checkbox"/> Liver <input checked="" type="checkbox"/>	Kidney <input checked="" type="checkbox"/> Pancreas <input checked="" type="checkbox"/> Intestine <input checked="" type="checkbox"/>
Cardiac Arrest/Downtime	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	Intraoperative time lapse from liver to pancreas removal from the peritoneal cavity:	0 Hours 59 Mins.	
CPR / Time	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	Organs Discarded	Heart <input type="checkbox"/> Lung <input type="checkbox"/> Liver <input type="checkbox"/>	Kidney <input type="checkbox"/> Pancreas <input type="checkbox"/> Intestine <input type="checkbox"/>
Total Est. Downtime	None	Blood Culture	No Growth after 1 day/s incubation	
Date /Time of Admission	11/06/2020 16:00 EST	PHS High Risk	YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>	
		Acute Lung Injury	Pleural effusion and or atelectasis	

*Cold Ischemia time is calculated from time of cross clamp to start of enzyme perfusion for islet isolation.



HPAP-073 Donor Summary

Medical History:

		Duration	Medications	Compliance
Type of Diabetes	T1D	6-10 years	Initially Insulin(IV) and now Metformin	yes
History of cancer	----	----	----	----
CAD	----	----	----	----
Hypertension	----	----	----	----
Hyperlipidemia	Yes	6 Months	Atorvastatin	
Autoimmune disease	----	----	----	----
Family History	CAD <input type="checkbox"/>	Diabetes <input checked="" type="checkbox"/>	Auto immune disease <input type="checkbox"/>	Others:
Surgical History:	None			
Comments:	Brothers and parents had diabetes Social Hx: smoker ½-1 pk /month/2 years, Etoh(Beer/6pack every few days/2years			

Hemodynamic Profile

Average BP During Hospitalization (mmHg)	125/68	
Average Low BP During Hospitalization	111/61	Duration: 15 min
Average BP in OR (mmHg)	120/80	
Average Low BP in OR (mmHg)	77/48	Duration: 5 min
Average HR in OR (bpm)	115	
ABG-pH range	7.19 - 7.47	

INTERVENTION

Blood Products/Meds Transfused Before Organ Recovery

Product	Amount (ml)	Units	Total (ml)
Fresh Frozen Plasma	----	----	----
PRBCs	----	----	----
Platelets	----	----	----
Norepinephrine (Levophed)	----	----	----
Vasopressin	----	0.04 UNITS/HR for the duration of 6:58:59 H	
Neo-Syneprine	----	----	----
Epinephrine	----	----	----
Phenylephrine	----	22 MCG/KG/MIN for the duration of 21 hrs	
Dopamine	----	----	----

HPAP-073 Donor Summary



Blood Products/Meds Transfused Intraoperative

Product	Amount (ml)	Units	Total (ml)
Fresh Frozen Plasma	-----	-----	-----
PRBCs	-----	-----	-----
Platelets	-----	-----	-----
Norepinephrine (Levophed)	-----	-----	-----
Vasopressin	-----	-----	-----
Neo-Syneprine (phenylephrine)	-----	-----	-----
Epinephrine	-----	-----	-----
Dopamine	-----	-----	-----
Heparin	-----	30,000	-----

Initial Autoantibody Screening (nPOD): ELISA

GAD-65	IA-2
ND	ND

Confirmatory results: Radioimmuno Assay (RIA)

	GAD-65 (unit/ml)	IA-2 (unit/ml)	Insulin AAB (unit/ml)	ZnT8 (unit/ml)
Results	1	0	0.001	0.003
Cut-off values	20	5	0.010	0.020

*Sample obtained at time of organ recovery.

	C-peptide (ng/ml)	Proinsulin
Results	0.17	ND

*Sample obtained at time of organ recovery.

HLA (OPO)*

Class 1	A	2	31	Class II	DR	8	11
	B	40:05	51		DR51	N-Negative	N-Negative
	C	02	10		DR52	52	52
	Bw4	Positive			DR53	N-Negative	N-Negative
	Bw6	Positive			DQB1	7	
			DQA1		05		
			DPB1		04:01	04:02	
Comment:							



HPAP-073 Donor Summary

Confirmatory HLA (UPENN)*

Class 1	A	02:01	31:01	Class II	DRB1	08:02	11:01
	B	40:05	51:01		DRB3	02:02	
	C	02:02	03:04		DRB4		
					DRB5		
					DQB1	03:01	
					DQA1	05:03	05:05
					DPB1	04:01	04:02
					DPA1	01:03	

*HLA typing performed using NGS

Infectious Disease Serology

Test	Result	Hemo/Plasma Dilution Status	
		Qualified	Non-Qualified
EBV IgG	Positive	✓	-
EBV IgM	Negative	✓	-
CMV	Positive	✓	-
HBcAb	Non- Reactive	✓	-
HBsAg	Non- Reactive	✓	-
HCV Ab	Non- Reactive	✓	-
HIV I/II	Non- Reactive	✓	-
Syphilis	Non- Reactive	✓	-
Procleix Ultrio	--	--	--
Ultrio HBV	Non- Reactive	✓	-
Ultrio HCV	Non- Reactive	✓	-
Ultrio HIV	Non- Reactive	✓	-
Toxoplasma Ab	Negative	✓	-
SARS-CoV-2	Negative	✓	

HPAP-073 Donor Summary



Laboratory Panel

	Initial	Peak	Terminal
Na (mEq/L) (135-145)	139	156	146
Creatinine (<1.5)	0.9	0.9	0.57
Glucose (mg/dL) (60-150)	427	427	208
HbA1C%	8.2	-	-
Total bilirubin (0-1.0)	0.6	2.4	1.2
SGOT (AST) (0-40)	33	33	18
SGPT (ALT) (5-35)	37	37	15
Alkaline phosphatase (45-110)	118	118	61
Serum Amylase (23-851)	44	44	38
Serum Lipase (0-80)	26	26	21
WBC (THO/uL) (4.5-11.0)	112.2	112.2	7
Hgb (g/dL) (12-16)	14.8	14.8	9.2
Platelets (THO/uL) (150-350)	225	225	129
INR (<2.0)	1.1	1.6	1.4

Urinalysis

	1 st	2 nd	3 rd	4 th
Glucose	Positive (50)	Positive (>500)	Positive (>500)	Positive (>=500)

Medications During Hospitalization

Steroids**	Solumedrol
Diuretics	Lasix(furosemide)
T3 Protocol	----
T4 Protocol*	Yes
Insulin**	yes
Antihypertensive	-----
Vasodilators	-----
DDAVP**	-----
Total parenteral nutrition	---
Other	Specify

*T4 protocol: Levothyroxine, (20 mcgs), Solumedrol (2 gms,) Dextrose 50%, (1 amp), Regular Insulin (20u), Vasopressin (1 unit)

Mi Z, Novitzky D, Collins JF, Cooper D KC. The optimal hormonal replacement modality selection for multiple organ procurement from brain-dead organ donors. Clinical Epidemiology 2015;7 17-27.

** Excluding T4 Protocol